Paclitaxel and Cisplatin-Induced Neurotoxicity: A Protective Role of Acetyl-L-Carnitine

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5756-5767

  Pisano, Claudio ^a,d   Pratesi, Graziella ^b   Laccabue, Diletta ^b   Zunino, Franco ^b   Giudice, Pietro Lo ^a   Bellucci, Augusta ^a   Pacifici, Licia ^a   Camerini, Barbara ^a   Vesci, Loredana ^a   Castorina, Massimo ^a   Cicuzza, Sandra ^a   Tredici, Giovanni ^c   Marmiroli, Paola ^c   Nicolini, Gabriella ^c   Galbiati, Stefania ^c   Calvani, Menotti ^a   Carminati, Paolo ^a   Cavaletti, Guido ^c  

^a S T SpA Indust Farmaceut Riu   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Dept of Oncol Res and Devmt   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; LEVACECARNINE; NERVE GROWTH FACTOR; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SENSORY NERVE CONDUCTION; TISSUE SPECIFICITY;

ACETYLCARNITINE; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; FEMALE; GANGLIA, SPINAL; HELA CELLS; HUMANS; LUNG NEOPLASMS; MALE; MODELS, ANIMAL; NEUROTOXINS; OVARIAN NEOPLASMS; PACLITAXEL; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR;

EID: 0345060438     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Meijer, C., de Vries, E. G., Marmiroli, P., Tredici, G., Frattola, L., and Cavaletti, G. Cisplatin-induced DNA platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology, 20: 883-887, 1999.
2. De Santis, S., Pace, A., Bove, L., Cognetti, F., Properzi, F., Fiore, M., Triaca, V., Savarese, A., Simone, M. D., Jandolo, B., et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin. Cancer Res., 6: 90-95, 2000.
3. Aloe, L., Manni, L., Properzi, F., De Santis, S., and Fiore, M. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by Cisplatin: behavioral, structural and biochemical analysis. Auton. Neurosci., 86: 84-93, 2000.
4. Cavaletti, G., Pezzoni, G., Pisano, C., Oggioni, N., Sala, F., Zoia, C., Ferrarese, C., Marmiroli, P., and Tredici, G. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci. Lett., 322: 103-106, 2002.
5. Apfel, S. C. Neurotrophic factors in peripheral neuropathies: therapeutical implications. Brain Pathol., 9: 393-413, 1999.
6. Apfel, S. C., Arezzo, J. C., Lipson, L. A., and Kessler, J. A. Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol., 31: 76-80, 1992.
7. Schmidt, Y., Unger, I., Bartke, R., and Reiter, R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (cd/db) mice. Exp. Neurol., 132: 16-23, 1995.
8. Tredici, G., Braga, M., Nicolini, G., Miloso, M., Marmiroli, P., Schenone, A., Nobbio, L., Frattola, L., and Cavaletti, G. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp. Neurol., 159: 551-558, 1999.
9. Moos, P. J., and Fitzpatrick, F. A. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. USA, 95: 3896-3901, 1998.
10. Apfel, S. C., Lipton, R. B., Arezzo, J. C., and Kessler, J. A. Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol., 29: 87-90, 1991.
11. Fritz, I. B. Carnitine and its role in fatty acid metabolism. Adv. Lipid Res., 1: 285-334, 1963.
12. Bremer, J. Carnitine metabolism and functions. Physiol. Rev., 63: 1420-1480, 1983.
13. Stanley, C. A. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv. Pediatr., 34: 59-88, 1987.
14. Bieber, L. L. Carnitine. Annu. Rev. Biochem., 57: 261-283, 1988.
15. Lowitt, S., Malone, J. I., Salem, A. F., and Korthals, J., Benford, S. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism, 44: 677-680, 1995.
16. Di Giulio, A. M., Lesma, E., and Gorio, A. Diabetic neuropathy in the rat: 1. ALC augments the reduced levels and axoplasmic transport of substance P. J. Neurosci. Res., 40: 414-419, 1995.
17. Kano, M., Kawakami, T., Hori, H., Hashimoto, Y., Tao, Y., Ishikawa, Y., and Takenaka, T. Effects of ALC on the fast axoplasmic transport in cultured sensory neurons of streptozotocin-induced diabetic rats. Neurosci. Res., 33: 207-213, 1999.
18. Fernandez, E., Pallini, R., Tamburrini, G., Lauretti, L., Tancredi, A., and La Marca, F. Effects of levo-acetylcarnitine on second motoneuron survival after axotomy. Neurol. Res., 17: 373-376, 1995.
19. Piovesan, P., Pacifici, L., Taglialatela, G., Ramacci, M. T., and Angelucci, L. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res., 633: 77-82, 1994.
20. NGFR) mRNA level in the central nervous system of aged rats. Prog. Neuropsychopharmacol. Biol. Psych., 19: 117-133, 1995.
21. Fanti, L., Berloco, M., and Pimpinelli, S. Carnitine suppression of position-effect variegation in Drosophila melanogaster. Mol. Gen. Genet., 244: 588-595, 1994.
22. Pomponi, M. G., and Neri, G. Butyrate and Acetyl-l-carnitine inhibit the Cytogenetic expression of the fragile X in vitro. Am. J. Med. Gen., 51: 447-450, 1994.
23. Cavaletti, G., Cavalletti, E., Montaguti, P., Oggioni, N., De Negri, O., and Tredici, G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology, 18: 137-146, 1997.
24. Cavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., and Fabbrica, D. Morphometric study of the sensory neurones and peripheral nerve changes induced by chronic cisplatin (DDP) administration. Acta Neuropathol., 84: 364-371, 1992.
25. Cavaletti, G., Minoia, C., Schieppati, M., and Tredici, G. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int. J. Radiat. Oncol. Biol. Phys., 29: 771-776, 1994.
26. Tredici, G., Cavaletti, G., Petruccioli, M. G., Fabbrica, D., Tedeschi, M., and Venturino, P. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology, 15: 701-704, 1994.
27. Skehan, P., Stoneng, R., Scudiero, D., Monks, A., Mc Mahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kennedy, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
28. Pratesi, G., Manzotti, C., Tortoreto, M., Prosperi, E., and Zunino, F. Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori, 75: 60-65, 1989.
29. Geldof, A. A. Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J. Cancer Res. Clin. Oncol., 121: 657-660, 1995.
30. Land, H., Parada, L. F., and Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (Lond.), 304: 596-602, 1983.
31. Caruso, M., Martelli, F., Giordano, A., and Felsani, A. Regulation of MyoD gene transcription and protein function by the transforming domains of the adenovirus E1A oncoprotein. Oncogene, 8: 267-278, 1993.
32. Tirone, F., and Shooter, E. M. Early gene regulation by nerve growth factor in PC12 cells: induction of an interferon-related gene. Proc. Natl. Acad. Sci. USA, 86: 2088-2092, 1989.
33. Lin, R., Leone, J. W., Cook, R. G., and Allis, C. D. Antibodies specific to acetylated histones document the existence of deposition- and transcription-related histone acetylation in Tetrahymena. J. Cell Biol., 108: 1577-1588, 1989.
34. Arends, M. J., Morris, R. G., and Wyllie, A. M. Apoptosis, the role of the endonucleases. Am. J. Pathol., 3: 593-608, 1990.
35. van der Westhuyzen, D. R., Bohm, E. L., and von Holt, C., Fractionation of chicken erythrocyte whole histone into the six main components by gel exclusion chromatography. Biochim. Biophys. Acta, 359: 341-345, 1974.
36. Laemmli, U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
37. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
38. Taglialatela, G., Angelucci, L., Ramacci, M. T., Werrbach-Perez, K., Jackson, G. R., and Perez-Polo, R. Stimulation of nerve growth factor receptor in PC12 cells by acetyl-1-carnitine. Biochem. Pharmacol., 44: 577-585, 1992.
39. Sussman, M. A., Battenberg, E., Bloom F. E., and Fowler, V. M. Identification of two nerve growth factor-induced polypeptides in PC12 cells. J. Mol. Neurosci., 2: 163-174, 1990.
40. Milbrandt, J. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science (Wash. DC), 238: 797-800, 1987.
41. Lemaire, P., Revelant, O., Bravo, R., and Charney, P. Two mouse genes encoding potential transcription factors with identical DNA-binding domains an activated by growth factors in cultured cells. Proc. Natl. Acad. Sci. USA, 85: 4691-4695, 1988.
42. Janssen-Timmen, U., Lemaire, P., Mattei, M. G., Revelant, O., and Charnay, P. Structure, chromosome mapping and regulation of mouse zinc-finger gene Krox-24; evidence for a common regulatory pathway for immediate-early serum-response genes. Gene, 80: 325-336, 1989.
43. Alberts, A. D., Peng, Y. M., Moon, T. E., and Bressler, R. Carnitine prevention of adriamycin toxicity in mice. Biomedicine, 29: 265-268, 1978.
44. Eriksson, N. P., Lindsay, R. M., and Alskogius, H. BDNF and NT-3 rescue sensory but not motoneurons following axotomy in the neonate. Neuroreport, 5: 1445-1448, 1994.
45. Gao, W. Q., Dybdal, N., Shinsky, N., Murnane, A., Schmelzer, C., Siegel, M., Keller, G., Hefti, F., Phillips, H. S., and Winslow, J. W. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol., 38: 30-37, 1995.
46. Hayakawa, K., Soube, G., Itoh, T., and Mitsuma, T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol on adult rat sympathetic ganglion explants in vitro. Life Sci., 54: 519-525, 1994.
47. Malgrange, B., Delrée, P., Rigo, J. M., Baron, H., and Moonen, G. Image analysis of neurite regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and its prevention by nerve growth factor or fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3, J. Neurosci. Meth., 53: 111-122, 1994.
48. Windebank, A. J., Smith, A. G., and Russell, J. W. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology, 44: 488-494, 1994.
49. Apfel, S. C., Kessler, J. A., Adornato, B. T., Litchy, W. J., Sanders, C., Rask, C. A. and the NGF Study Group. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology, 51: 695-702, 1998.
50. Grunstein, M. Histone function in transcription. Annu. Rev. Cell Biol., 6: 643-678, 1990.
51. Morse, R. H. Transcribed chromatin. Trends Biochem. Sci., 17: 23-26, 1992.
52. Turner, B. M. Decoding the nucleosome. Cell, 75: 5-8, 1993.
53. Turner, B. M., and O'Neill, L. P. Histone acetylation in chromatin and chromosomes. Semin. Cell Biol., 6: 229-236, 1995.
54. Huang, R. P., Liu, C., Fan, Y., Mercola, D., and Adamson, E. D. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res., 55: 5054-5062, 1995.
55. Huang, R. P., Fan, Y., de Belle, I., Niemeyer, C., Gottardis, M. M., Mercola, D., and Adamson, E. D. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int. J. Cancer, 72: 102-109, 1997.
56. Huang, R. P., Darland, T., Okamura, D., Mercola, D., and Adamson, E. D. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. Oncogene, 9: 1366-1377, 1994.
57. Braddock, M. The transcription factor Egr-1: a potential drug in wound healing and tissue repair. Brain Res. Rev., 28: 370-490, 1998.
58. O'Neill, L. P., and Turner, B. M. Histone H4 acetylation distinguishes coding regions of the human genome from heterochromatin in a differentiation-dependent but transcription-independent manner. EMBO J., 14: 3946-3957, 1995.
59. Mamorstein, R., and Roth, S. Y. Histone acetyltransferases: function, structure and catalysis. Curr. Opin. Genes Dev., 11: 155-161, 2001.
60. Strahl, B. D., and Allis, C. D. The language of covalent histone modifications. Nature (Lond.), 403: 41-45, 2000.
61. Grunstein, M., Histone acetylation in chromatin structure and transcription. Nature (Lond.), 389: 349-352, 1997.
62. Sterner, D. E., and Berger, S. L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev., 64: 435-459, 2000.
63. Kuo, M. H., and Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays, 20: 615-626, 1998.
64. Pazin, M. J., and Kadonaga, J. T. What's up and down with histone deacetylation and transcription? Cell, 89: 325-328, 1997.
65. Loidl, P. Histone acetylation: facts and questions. Chromosoma. 103: 441-449, 1994.
66. Rebouche, C. J., and Paulson, D. J. Carnitine metabolism and function in humans. Annu. Rev. Nutr., 6: 41-66, 1986.